Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 3Phase 3 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma 6Leukemia 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Non-Hodgkin 4Recurrence 3Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Follicular 2Leukemia, T-Cell 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Congenital Abnormalities 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Small Cell Lung Carcinoma 1Seminoma 1Sarcoma, Ewing 1Retinoblastoma 1Primary Myelofibrosis 1Polycythemia Vera 1Neuroblastoma 1Neoplasms 1Myeloproliferative Disorders 1

Interventions

Temozolomide 8Lomustine 4vocimagene amiretrorepvec 2Radiation 2veliparib 1tinostamustine 1regorafenib 1carbon-11 acetate 1antisecretory factor 1Sunitinib 1Standard of Care 1Radiotherapy 1Magnetic Resonance Spectroscopy 1Irinotecan 1GDC-0084 1Flucytosine 1Etoposide 1Drug Therapy 1Disulfiram 1Dianhydrogalactitol 1DNA 1Copper 1Carbon-11 1Bevacizumab 1Alkylating Agents 1AZD1390 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Glioblastoma × Etoposide × Clear all
NCT06105619 2026-01-20

A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

Beijing Pearl Biotechnology Limited Liability Company

Phase 2/3 Active not recruiting
84 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡